← brief for 2026-10-25 · Regeneration & devices

Peritoneal M2 macrophage-derived extracellular vesicles as a nanotherapeutic for immune-oxidative microenvironment reprogramming in IgA nephropathy.

Key takeaways

This study was done in mice, not people yet. It tested a new cell therapy for a common kidney disease. The therapy helped reduce protein in the urine and scarring. It is a promising step, but more testing is needed.

Who did this work

Zhang X (Department of Nephrology, West China Hospital of Sichuan University, Chengdu, 610041, China. [email protected].) · Li L (Department of Nephrology, West China Hospital of Sichuan University, Chengdu, 610041, China. [email protected].) · Li L (NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, 610041, China.) · Dai W (Core Facilities of West China Hospital, Chengdu, Sichuan, 610041, China.) · Hu L (West China-California Research Center for Predictive Intervention Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.) · Zhou Y (Animal experimental center of West China hospital, Sichuan University, Chengdu, 610041, China.) · Zhang W (Core Facilities of West China Hospital, Chengdu, Sichuan, 610041, China.) · Gou L (Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu, 610041, China. [email protected].) · Cao Q (Centre for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.) · Hu Z (Department of Nephrology, West China Hospital of Sichuan University, Chengdu, 610041, China. [email protected].) · Wang C (Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu, 610041, China. [email protected].)

Source

Article · Europe PMC, CKD · 2026-10-23
https://doi.org/10.1039/d6tb01585a